Clinical Trial

Mirror Therapy Rehabilitation of the Upper Limb After Stroke (NEURO-MIROIR 2)

Study acronym: NEUROMIROIR2
Recruiting
View on ClinicalTrials.gov →
Summary
Hemiparesis is a common motor disorder after a stroke. The majority of patients do not recover functional use of their paretic upper limb. The use of mirror therapy allows the activation of the mirror neurons involved to stimulate brain plasticity after brain damage.The IVS (Intensive Visual Stimulation) device allows an easy implementation of mirror therapy by filming the valid upper limb and projecting the inverted image onto a screen placed above the parietal arm thus producing the illusion of movement of the parietal arm. The main hypothesis of this study is that the structured practice of a large number of upper limb targeted movement repetitions using an intensive visual numerical simulation device as a partial replacement for routine care (conventional occupational therapy) in the sub-acute phase of stroke will increase the active function (motor function and functional abilities) of the distal end of the upper limb compared to conventional rehabilitation. Objectives: This randomized controlled trial will evaluate the effects of partial substitution of routine care (occupational therapy) by structured movement repetition programs by Intensive Visual Simulation using an IVS3 device, on the distal motor control of the upper hemiparesis limb, between 4 and 10 weeks after the stroke, compared to a program with conventional care alone.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2019-10-07; most recent amendment 2026-03-16.
Status change: Not Yet Recruiting → Recruiting 2020-01-22
Trial Details
NCT Number NCT04119544
Lead Sponsor Clinique Les Trois Soleils
Collaborators: Clinalliance Villiers-sur-Orge, Centre de Rééducation Fonctionnelle Pasori, CHU de Reims, Clinique Les Grands Chênes, Clinique Napoléon, Clinique Mariénia, Clinique Verdaich
Conditions Stroke
Enrollment 66 participants
Start Date 2019-12-10
Primary Completion 2027-07-31 (estimated)
Study Completion 2028-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-18